Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Parravano, Mariacristina ^a   Menchini, Francesca ^b   Virgili, Gianni ^c  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

ANTERIOR EYE CHAMBER DISEASE; ANTIANGIOGENIC THERAPY; BIOMICROSCOPY; CATARACT; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOPHTHALMITIS; HUMAN; INTERMETHOD COMPARISON; INTRAOCULAR HYPERTENSION; LASER COAGULATION; OPTICAL COHERENCE TOMOGRAPHY; PATIENT COMPLIANCE; REVIEW; RISK BENEFIT ANALYSIS; STEREOSCOPIC VISION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UVEITIS; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 77949436790     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007419.pub2     Document Type: Review

References (47)

1. Ahmadieh 2008 {published data only} Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, et al.Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Archive for Clinical & Experimental Ophthalmology 2008;246(4):483-9.
2. Macugen 2005 {published data only} Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112(10):1747-57.
3. Paccola 2008 {published data only} Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). British Journal of Ophthalmology 2008;92(1):76-80.
4. Soheilian 2007 {published data only} Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, et al.Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007;27(9):1187-95.
5. * Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al.Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116(6):1142-50.
6. DRCRnet 2007 {published data only} Diabetic Retinopathy Clinical Research Network. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, et al.A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114(10):1860-7.
7. Faghihi 2008 {published data only} Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, et al.Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. European Journal of Ophthalmology 2008;18(6):941-8.
8. Aiello 2005 Aiello LP. Angiogenic pathways in diabetic retinopathy. New England Journal of Medicine 2005;353(8):839-41.
9. Antcliff 1999 Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Seminars in Ophthalmology 1999;14(4):223- 32.
10. Arevalo 2007 Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG,Wu L, Maia M, et al. Pan-American Collaborative Retina Study Goup. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114(4):743-50.
11. Aroca 2004 Aroca PR, Salvat M, Fernandez J, Mendez I. Risk factors for diffuse and focal macular edema. Journal of Diabetic Complications 2004; 18(4):211-5.
12. Avery 2006 Avery RL, Pieramici DJ, Rabena MD. Intravitreal bevacizumab (Avastin) for neovascular age related macular degeneration. Ophthalmology 2006;113(3):363-72.
13. Borm 2009 Borm GF, Lemmers O, Fransen J, Donders R. The evidence provided by a single trial is less reliable than its statistical analysis suggests. Journal of Clinical Epidemiology 2009;62(7):711-5.
14. Bresnick 1976 Bresnick GH, Engerman R, Davis MD, de Venecia G, Myers FL. Patterns of ischemia in diabetic retinopathy. Transactions. Section on Ophthalmology. American Academy of Ophthalmology and Otolaryngology 1976;81(4 Pt 1):OP694-709.
15. Bresnick 1983 Bresnick GH. Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology 1983;90(11): 1301-17.
16. Bresnick 1984 Bresnick GH, Condit R, Syriala S, Palta M, Groo A, Korth K. Abnormalities of the foveal avascular zone in diabetic retinopathy. Archives of Ophthalmology 1984;102(9):1286-93.
17. Brown 2004 Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Archives of Ophthalmology 2004;122(3):330-5.
18. Ciulla 2003 Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003;26(9):2653-64.
19. Ciulla 2004 Ciulla TA,Walker JD, Fong DS, Criswell MH. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Current Opinions in Ophthalmology 2004;15(3): 211-20.
20. Cunha-Vaz 1998 Cunha-Vaz J. Diabetic macular edema. European Journal of Ophthalmology 1998;8(3):127-30.
21. Cunningham 2005 Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112(10):1747-57.
22. Deeks 2008 Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochranehandbook.org.
23. ETDRS 1985 Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Archives of Ophthalmology 1985;103(12):1796-806.
24. Ferrara 2004 Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews. Drug Discovery 2004;3(5):391-400.
25. Ferrara 2006 Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26(8):859-70.
26. Ferris 1984 Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Archives of Ophthalmology 1984;102(11):1640-2.
27. Frank 2004 Frank RN. Diabetic Retinopathy. New England Journal of Medicine 2004;350(1):48-58.
28. Glanville 2006 Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
29. Gragoudas 2004 Gragoudas ES, Adamis AP, Cunningham ET Jr. Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. New England Journal of Medicine 2004;351(27): 2805-16.
30. Harbour 1996 Harbour JW, Smiddy WE, Flynn HW Jr, Rubsamen RE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. American Journal of Ophthalmology 1996;121(4):405-13.
31. Higgins 2008a Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
32. Higgins 2008b Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
33. Iturralde 2006 Iturralde D Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al.Intravitreal bevacizumab (Avastin) treatment of macular edema in central retina vein occlusion: a short-term study. Retina 2006;26(3):279-84.
34. Klein 1984 Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91(12):1464-74.
35. Kylstra 1999 Kylstra JA, Brown JC, Jaffe GJ, et al.The importance of fluorescein angiography in planning laser treatment of diabetic macular edema. Ophthalmology 1999;106(11):2068-73.
36. Ladas 1993 Ladas ID, Theodossiadis GP. Long-term effectiveness of modified grid laser photocoagulation for diffuse diabetic macular edema. Acta Ophthalmologica 1993;71(3):393-7.
37. Lee 1991 Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991;98(10):1594-602.
38. Lewis 1992 Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992;99(5):753-59.
39. O'Doherty 2008 O'Doherty M, Dooley I, Hickey-Dwyer M. Interventions for diabetic macular oedema: a systematic review of the literature. British Journal of Ophthalmology 2008;92(12):1581-90.
40. Presta 1997 Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al.Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Research 1997;57(20):4593-9.
41. Rosenfeld 2006 Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmology Clinics of North America 2006; 19(3):361-72.
42. Spaide 2006 Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26(3):275-8.
43. Ticho 1973 Ticho U, Patz A. The role of capillary perfusion in the management of diabetic macular edema. American Journal of Ophthalmology 1973;76(6):880-6.
44. Tranos 2004 Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE. Macular edema. Survey of Ophthalmology 2004;49(5):470-90.
45. Vedula 2008 Vedula SS, Krzystzolyk MG. Antiangiogenic therapy with antivascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005139.pub2]
46. White 2008 White IR, Higgins JP, Wood AM. Allowing for uncertainty due to missing data in meta-analysis - Part 1. Two-stage methods. Statistics in Medicine 2008;27(5):711-27.
47. Williams 2004 Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 2004;18(10):963-83.